In vivo, KPNA2 knockdown markedly reduced tumor weight and tumor volumes while IRF2 knockdown promoted tumor growth, and IRF2 knockdown could weaken KPNA2 knockdown-medicated tumor growth inhibition (Figures 3(e) and 3(f)). The gene discussed is KPNA2; the disease is neoplasm.